These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 16400341)
1. Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation. Atsuta Y; Suzuki R; Yamamoto K; Terakura S; Iida H; Kohno A; Naoe T; Yano K; Wakita A; Taji H; Hamaguchi M; Kodera Y; Sao H; Morishima Y; Hamajima N; Morishita Y Bone Marrow Transplant; 2006 Feb; 37(3):289-96. PubMed ID: 16400341 [TBL] [Abstract][Full Text] [Related]
2. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914 [TBL] [Abstract][Full Text] [Related]
3. Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients. Diaz MA; Vicent MG; Gonzalez ME; Verdeguer A; de la Rubia J; Bargay J; de Arriba F; Diez JL; Caballero D; Madero L; Brunet S; Bone Marrow Transplant; 2004 Sep; 34(5):433-8. PubMed ID: 15273704 [TBL] [Abstract][Full Text] [Related]
4. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Akpek G; Lee SM; Anders V; Vogelsang GB Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216 [TBL] [Abstract][Full Text] [Related]
5. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation. Sohn SK; Kim DH; Baek JH; Kim JG; Lee KB; Lee KH; Lee JH; Choi SJ; Lee JH; Shin IH Bone Marrow Transplant; 2006 Apr; 37(7):699-708. PubMed ID: 16501588 [TBL] [Abstract][Full Text] [Related]
6. Chronic graft-versus-host disease: a prospective cohort study. Arora M; Burns LJ; Davies SM; Macmillan ML; Defor TE; Miller WJ; Weisdorf DJ Biol Blood Marrow Transplant; 2003 Jan; 9(1):38-45. PubMed ID: 12533740 [TBL] [Abstract][Full Text] [Related]
7. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y; Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494 [TBL] [Abstract][Full Text] [Related]
8. [Analysis of chronic graft-versus-host disease after unrelated-donor bone marrow transplantation. Kanazawa University Bone Marrow Transplant Team]. Takami A; Nakao S; Ueda M; Takamatsu H; Sugimori N; Yamazaki H; Miura H; Ito K; Yamaguchi M; Niki T Rinsho Ketsueki; 1995 Jan; 36(1):6-11. PubMed ID: 7715080 [TBL] [Abstract][Full Text] [Related]
9. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686 [TBL] [Abstract][Full Text] [Related]
10. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Zaja F; Bacigalupo A; Patriarca F; Stanzani M; Van Lint MT; Filì C; Scimè R; Milone G; Falda M; Vener C; Laszlo D; Alessandrino PE; Narni F; Sica S; Olivieri A; Sperotto A; Bosi A; Bonifazi F; Fanin R; Bone Marrow Transplant; 2007 Aug; 40(3):273-7. PubMed ID: 17549053 [TBL] [Abstract][Full Text] [Related]
11. Time of onset, viral load, relapse, and duration of active cytomegalovirus infection in bone marrow transplant outcomes. Habib K; Lamia T; Amel L; Abdelrahmen A; Saloua L; Hana E; Amine S; Bechir Z; Tarek BO; Assia BH Exp Clin Transplant; 2008 Mar; 6(1):67-73. PubMed ID: 18405248 [TBL] [Abstract][Full Text] [Related]
12. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583 [TBL] [Abstract][Full Text] [Related]
13. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy. Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257 [TBL] [Abstract][Full Text] [Related]
14. Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients. Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH Eur J Haematol; 2007 Apr; 78(4):338-46. PubMed ID: 17378893 [TBL] [Abstract][Full Text] [Related]
15. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Jagasia M; Giglia J; Chinratanalab W; Dixon S; Chen H; Frangoul H; Engelhardt B; Goodman S; Greer J; Kassim A; Morgan D; Ruffner K; Schuening F Biol Blood Marrow Transplant; 2007 Oct; 13(10):1207-15. PubMed ID: 17889358 [TBL] [Abstract][Full Text] [Related]
16. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755 [TBL] [Abstract][Full Text] [Related]
17. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies. Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920 [TBL] [Abstract][Full Text] [Related]
18. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Arora M; Nagaraj S; Wagner JE; Barker JN; Brunstein CG; Burns LJ; Defor TE; McMillan ML; Miller JS; Weisdorf DJ Biol Blood Marrow Transplant; 2007 Oct; 13(10):1145-52. PubMed ID: 17889350 [TBL] [Abstract][Full Text] [Related]
19. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A; Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791 [TBL] [Abstract][Full Text] [Related]
20. Transplantation outcome in allogeneic PBSCT patients according to a new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive-type onset. Sohn SK; Kim DH; Kim JG; Lee NY; Suh JS; Lee KS; Lee KB Bone Marrow Transplant; 2004 Jul; 34(1):63-8. PubMed ID: 15133486 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]